{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:55:32Z","timestamp":1789437332635,"version":"build-2803163510"},"reference-count":34,"publisher":"FapUNIFESP (SciELO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS.<\/jats:p>","DOI":"10.1590\/s0004-282x2011000600005","type":"journal-article","created":{"date-parts":[[2011,10,29]],"date-time":"2011-10-29T04:12:03Z","timestamp":1319861523000},"page":"751-755","source":"Crossref","is-referenced-by-count":18,"title":["Neuroleptic malignant syndrome"],"prefix":"10.1590","volume":"69","author":[{"given":"Mariana","family":"Moscovich","sequence":"first","affiliation":[{"name":"Pontifical Catholic University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe T.M.","family":"N\u00f3vak","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur F.","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Bruch","sequence":"additional","affiliation":[{"name":"Pontifical Catholic University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabita","family":"Tomelin","sequence":"additional","affiliation":[{"name":"Pontifical Catholic University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison M.","family":"N\u00f3vak","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato P.","family":"Munhoz","sequence":"additional","affiliation":[{"name":"Pontifical Catholic University of Paran\u00e1, Brazil; Federal University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lio A.G.","family":"Teive","sequence":"additional","affiliation":[{"name":"Federal University of Paran\u00e1, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","reference":[{"key":"ref1","first-page":"145","article-title":"A nonphenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychosis","volume":"118","author":"Delay J","year":"1960","journal-title":"Ann Med Psychol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson JL","year":"1985","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1176\/ps.49.9.1163","article-title":"Neuroleptic malignant syndrome: a review","volume":"49","author":"Pelonero A","year":"1998","journal-title":"Psychiatric Services","ISSN":"https:\/\/id.crossref.org\/issn\/1075-2730","issn-type":"print"},{"key":"ref4","first-page":"1780","article-title":"Neuroleptic malignant syndrome: mechanisms, interactions, and causality","volume":"25","author":"Gillman PK","year":"2010","journal-title":"Mov Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0855-3185","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bmj.288.6428.1399-a","article-title":"Neuroleptic malignant syndrome","volume":"288","author":"Szabadi E","year":"1984","journal-title":"Br Med J","ISSN":"https:\/\/id.crossref.org\/issn\/0007-1447","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","article-title":"Neuroleptic malignant syndrome","volume":"77","author":"Caroff SN","year":"1993","journal-title":"Med Clin North Am","ISSN":"https:\/\/id.crossref.org\/issn\/0025-7125","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn JR","year":"2007","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref8","first-page":"833","article-title":"Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine","volume":"56","author":"Hanel RA","year":"1998","journal-title":"Arq Neuropsiquiatr","ISSN":"https:\/\/id.crossref.org\/issn\/0004-282X","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/archinte.1987.00370080133023","article-title":"Metoclopramide-induced neuroleptic malignant syndrome","volume":"147","author":"Friedman LS","year":"1987","journal-title":"Arch Intern Med","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.encep.2007.11.007","article-title":"Neuroleptic malignant syndrome and atypical antipsychotics: a brief review","volume":"34","author":"Khaldi S","year":"2008","journal-title":"Encephale","ISSN":"https:\/\/id.crossref.org\/issn\/0013-7006","issn-type":"print"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4088\/JCP.08m04315","article-title":"Comparing acute toxicity of first-and second-generation antipsychotic drugs: a 10-year, retrospective cohort study","volume":"70","author":"Ciranni MA","year":"2009","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.v65n0403","article-title":"Neuroleptic malignant syndrome and atypical antipsychotic drugs","volume":"65","author":"Ananth J","year":"2004","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1345\/aph.18151","article-title":"Neuroleptic malignant syndrome associated with olanzapine","volume":"32","author":"Filice GA","year":"1998","journal-title":"Ann Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1176\/ajp.155.8.1113","article-title":"Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique","volume":"155","author":"Hasan S","year":"1998","journal-title":"Am J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1345\/aph.1L371","article-title":"Neuroleptic malignant syndrome secondary to quetiapine","volume":"43","author":"Gortney JS","year":"2009","journal-title":"Ann Pharmacother","ISSN":"https:\/\/id.crossref.org\/issn\/1060-0280","issn-type":"print"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3181b4b091","article-title":"Atypical neuroleptic malignant syndrome with quetiapine: a case report and review of the literature","volume":"29","author":"El-Gaaly S","year":"2009","journal-title":"J Clin Psychopharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200923060-00003","article-title":"Neuroleptic malignant syndrome associated with atypical antipsychotic drugs","volume":"23","author":"Trollor JN","year":"2009","journal-title":"CNS Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00007611-198805000-00035","article-title":"Neuroleptic malignant syndrome associated with metoclopramide","volume":"81","author":"Patterson JF","year":"1988","journal-title":"Southern Med J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00005053-198804000-00010","article-title":"Neuroleptic malignant syndrome following amoxapine overdose","volume":"176","author":"Taylor NE","year":"1988","journal-title":"J Nerv Mental Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3928\/0048-5713-19910301-10","article-title":"Pathogenesis of neuroleptic malignant syndrome","volume":"21","author":"Mann SC","year":"1991","journal-title":"Psychiatric Annals","ISSN":"https:\/\/id.crossref.org\/issn\/0048-5713","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0006-3223(93)90156-8","article-title":"Enzyme elevations in the neuroleptic malignant syndrome","volume":"34","author":"Gurrera R","year":"1993","journal-title":"Biol Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0924-9338(00)00402-8","article-title":"Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow","volume":"15","author":"Spivak B","year":"2000","journal-title":"Eur Psychiatry"},{"key":"ref23","first-page":"79","article-title":"The neuroleptic malignant syndrome","volume":"41","author":"Caroff SN","year":"1980","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref24","first-page":"18","article-title":"Mortality from neuroleptic malignant syndrome","volume":"50","author":"Shalev A","year":"1989","journal-title":"J Clin Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"key":"ref25","series-title":"The Neuroleptic malignant syndrome and related conditions.Washington,","author":"Lazarus A","year":"1989"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/070674379504000907","article-title":"Management of suspected neuroleptic malignant syndrome","volume":"40","author":"Velamoor VR","year":"1995","journal-title":"Can J Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0706-7437","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/cc5148","article-title":"Managing an effective treatment for neuroleptic malignant syndrome","volume":"11","author":"Reulbach U","year":"2007","journal-title":"Crit Care","ISSN":"https:\/\/id.crossref.org\/issn\/0270-7462","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0306-9877(92)90027-A","article-title":"A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome","volume":"38","author":"Weller M","year":"1992","journal-title":"Med Hypotheses","ISSN":"https:\/\/id.crossref.org\/issn\/0306-9877","issn-type":"print"},{"key":"ref29","first-page":"960","article-title":"Neuroleptic malignant syndrome in advanced Parkinson's disease","volume":"6","author":"Gordon PH","year":"2001","journal-title":"Mov Disord","ISSN":"https:\/\/id.crossref.org\/issn\/0855-3185","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bja\/85.1.129","article-title":"Neuroleptic malignant syndrome","volume":"85","author":"Adnet F","year":"2000","journal-title":"Br J Anaesth","ISSN":"https:\/\/id.crossref.org\/issn\/0007-0912","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hup.376","article-title":"Clinical risk factors for neuroleptic malignant syndrome","volume":"17","author":"Berardi D","year":"2002","journal-title":"Hum Psychopharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome","volume":"46","author":"Keck PE","year":"1989","journal-title":"Arch Gen Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"key":"ref33","first-page":"439","article-title":"Neuroleptic malignant syndrome: case report and discussion","volume":"169","author":"Chandran GJ","year":"2003","journal-title":"CMAJ","ISSN":"https:\/\/id.crossref.org\/issn\/0820-3946","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1007\/PL00014200","article-title":"The many varieties of catatonia","volume":"251","author":"Fink M","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci","ISSN":"https:\/\/id.crossref.org\/issn\/0940-1334","issn-type":"print"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v69n5\/a04v69n5.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T19:52:35Z","timestamp":1560887555000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2011000600005&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0004-282X2011000600005"],"URL":"https:\/\/doi.org\/10.1590\/s0004-282x2011000600005","relation":{},"ISSN":["0004-282X"],"issn-type":[{"value":"0004-282X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}